Umeclidinium Bromide/Vilanterol Trifenatate (Anoro Ellipta)

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

< PrevNext >

Umeclidinium Bromide/Vilanterol Trifenatate (Anoro Ellipta)

Common Drug Review

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Sep.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK525459PMID: 30212060

< PrevNext >

PubReader
Print View
Cite this Page
Umeclidinium Bromide/Vilanterol Trifenatate (Anoro Ellipta) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Sep.

Other titles in this collection

CADTH Common Drug Reviews

Related information

NLM Catalog
Related NLM Catalog Entries

Similar articles in PubMed

Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.[Lancet Respir Med. 2014]
Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, Church A. Lancet Respir Med. 2014 Jun; 2(6):472-86. Epub 2014 May 14.
Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study.[Clin Ther. 2014]
Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study.
Mehta R, Hardes K, Kelleher D, Preece A, Tombs L, Brealey N. Clin Ther. 2014 Jul 1; 36(7):1016-1027.e2. Epub 2014 Jun 17.
Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.[Int J Chron Obstruct Pulmon Di...]
Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR. Int J Chron Obstruct Pulmon Dis. 2017; 12:997-1008. Epub 2017 Mar 24.
Review The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.[Ther Adv Respir Dis. 2013]
Review The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
Feldman GJ, Edin A. Ther Adv Respir Dis. 2013 Dec; 7(6):311-9. Epub 2013 Sep 3.
Review Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease.[Drugs. 2015]
Review Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease.
Blair HA, Deeks ED. Drugs. 2015 Jan; 75(1):61-74.